Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects

Phase 1 Completed 24 enrolled LG Life Sciences

RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study is to investigate the drug interaction between LC15-0444 and pioglitazone by comparing the safety, tolerability and pharmacokinetics of LC15-0444 and pioglitazone are administered concomitantly and each alone in healthy male subjects.

Timeline

Start: 2009-02
Primary completion: 2009-06
Completion: 2009-12

Publications

Kim SE, Yi S, Shin KH, Kim TE, Kim MJ, Kim YH, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther. 2012 Jan;50(1):17-23. doi: 10.5414/cp201568.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemigliptin	Small molecule	200 mg	Oral
Subject	Pioglitazone	Small molecule	30 mg	Oral

Indications

No indication recorded.